Renflexis, Biosimilar for Remicade to Treat Crohn’s and UC, Approved by FDA

Renflexis, Biosimilar for Remicade to Treat Crohn’s and UC, Approved by FDA
Renflexis (infliximab-abda), a biosimilar of Remicade (infliximab), has been approved in the U.S. to treat a number of autoimmune diseases, including adult and pediatric Crohn’s disease and adult ulcerative colitis. Samsung Bioepis, which manufactures Renflexis, announced the U.S. Food and Drug Administration’s approval notice in a recent press release. The treatment was approved for use in Europe and Australia last year.

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *